NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis $1.75 0.00 (0.00%) Closing price 09/25/2026 03:59 PM EasternExtended Trading$1.75 0.00 (-0.17%) As of 09/25/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Silo Pharma Stock (NASDAQ:SILO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silo Pharma alerts:Sign Up Key Stats Today's Range$1.72▼$1.8150-Day Range$1.72▼$4.7152-Week Range$1.63▼$13.20Volume20,090 shsAverage Volume44,481 shsMarket Capitalization$2.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics and drug-delivery technologies for patients with conditions that have limited treatment options. The company’s approach combines traditional pharmaceutical compounds with psychedelic-related therapies and proprietary delivery systems designed to improve dosing, treatment duration, and patient administration. Silo Pharma’s pipeline has included programs targeting conditions such as fibromyalgia, post-traumatic stress disorder, Alzheimer’s disease, and rheumatoid arthritis. Its development efforts have featured SP-26, an implantable, controlled-release ketamine formulation being evaluated for potential use in fibromyalgia, as well as other investigational programs involving ketamine, psychedelic compounds, and intranasal or localized drug-delivery technologies. The company conducts its research and development activities primarily through collaborations with academic and scientific partners. Silo Pharma is headquartered in the United States and remains focused on advancing its preclinical and clinical-stage pipeline rather than commercializing an established portfolio of marketed medicines. Eric Weisblum has served in a leadership role as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Silo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreSILO MarketRank™: Silo Pharma scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSilo Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSilo Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Silo Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silo Pharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silo Pharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silo Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.90% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently decreased by 12.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.79 News SentimentSilo Pharma has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Silo Pharma this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders3.63% of the stock of Silo Pharma is held by insiders.Percentage Held by Institutions5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SILO Stock News HeadlinesReviewing Ensysce Biosciences (NASDAQ:ENSC) and Silo Pharma (NASDAQ:SILO)September 26 at 4:54 AM | americanbankingnews.comSilo Pharma Gets U.S. Patent Allowance For SPC-15 PTSD TreatmentSeptember 18, 2026 | rttnews.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 26 at 1:00 AM | Stansberry Research (Ad)Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd TreatmentSeptember 18, 2026 | marketscreener.comMSilo Pharma Receives USPTO Notice of Allowance for SPC-15 Patent Covering Stress-Induced Behavioral Response PreventionSeptember 18, 2026 | quiverquant.comQSilo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property PortfolioSeptember 18, 2026 | globenewswire.comSilo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation ForumSeptember 9, 2026 | rttnews.comSilo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 DevelopmentSeptember 9, 2026 | quiverquant.comQSee More Headlines SILO Stock Analysis - Frequently Asked Questions How have SILO shares performed this year? Silo Pharma's stock was trading at $5.10 at the beginning of 2026. Since then, SILO stock has decreased by 65.7% and is now trading at $1.75. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.44. Silo Pharma had a negative net margin of 6,726.39% and a negative trailing twelve-month return on equity of 81.75%. When did Silo Pharma's stock split? Silo Pharma shares reverse split on Wednesday, June 3rd 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 2nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX). Company Calendar Last Earnings8/13/2026Today9/26/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SILO's financial health is in the Red zone, according to TradeSmith. SILO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SILO CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.23 million Net Margins-6,726.39% Pretax Margin-8,283.33% Return on Equity-81.75% Return on Assets-66.35% Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$70 thousand Price / Sales39.75 Cash FlowN/A Price / Cash FlowN/A Book Value$7.10 per share Price / Book0.25Miscellaneous Outstanding Shares1,590,000Free Float1,530,000Market Cap$2.78 million OptionableNot Optionable Beta0.66 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SILO) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe No. 1 move you need to make before Musk’s “Starphone” goes mainstreamTech forecaster Josh Baylin, who briefed Congress on the iPhone years before its release, says Elon Musk is bu...Stansberry Research | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silo Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
